Dernières nouvelles

Information non disponible

27 enregistrements « 1 de 3 »

Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

Article de revue

JAMA Oncol, 10 (2), 2024.

Résumé | Liens:

Graham J, Ghosh S, Breau RH, Wood L, Tanguay S, Bosse D, Lalani AK, Bhindi B, Heng D, Finelli A, Fallah-Rad N, Castonguay V, Basappa NS, Soulières D, Pouliot F, Kollmannsberger C, Bjarnason GA

Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

Article de revue

Clin Genitourin Cancer, 2024.

Résumé | Liens:

Lalani AA, Kapoor A, Basappa NS, Bhindi B, Bjarnason GA, Bosse D, Breau RH, Canil CM, Cardenas LM, Castonguay V, Chavez-Munoz C, Chu W, Dudani S, Graham J, Heng DYC, Kollmannsberger C, Lattouf JB, Morgan S, Reaume MN, Richard PO, Swaminath A, Tanguay S, Wood LA, Lavallée LT

Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement

Article de revue

Can Urol Assoc J, 17 (5), 2023.

Résumé | Liens:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Article de revue

Cancer Lett, 553 , 2023.

Résumé | Liens:

Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Article de revue

Lancet Oncol, 24 (4), 2023.

Résumé | Liens:

Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D,

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Article de revue

J Clin Oncol, 41 (36), 2023.

Résumé | Liens:

Sawaya GB, Dragomir A, Wood LA, Kollmannsberger C, Basappa NS, Kapoor A, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Tanguay S

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Article de revue

Eur Urol Oncol, 2023.

Résumé | Liens:

Cardenas LM, Ghosh S, Finelli A, Wood L, Kollmannsberger C, Basappa N, Graham J, Heng D, Bjarnason G, Soulières D, Bossé D, Castonguay V, Saleh R, Tanguay S, Bhindi B, Breau RH, Pouliot F, Lalani AA

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

Article de revue

JCO Glob Oncol, 9 , 2023.

Résumé | Liens:

Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Heng D, Wood LA, Castonguay V, Soulières D, Winquist E, Canil C, Bjarnason GA, Breau RH, Pouliot F, Swaminath, A

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Article de revue

Adv Radiat Oncol, 7 (4), 2022.

| Liens:

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yanez E, Gumus M, Olivera Hurtado de Mendoza M, Samouelian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ,

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Article de revue

Obstet Gynecol Surv, 77 (1), 2022.

| Liens:

27 enregistrements « 1 de 3 »
Signaler des ajouts ou des modifications

Projets actifs

  • A Phase II, Multicentre, Open-label,[...]Efficacy and Safety of Datopotamab Deruxtecan(Dato-DXd) as Monotherapy[...]with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours(TROPION-PanTumor03)(sub-study 6:Bladder), du 2023-12-06 au 2028-12-25
  • A Phase Ill Randomized, Open-Label,...Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative...Muscle Invasive Bladder Cancer (VOLGA)... , du 2023-08-23 au 2028-12-25
Information provenant du registre des projets de recherche de l'Université Laval